|
US5652258A
(en)
*
|
1995-05-30 |
1997-07-29 |
Gliatech, Inc. |
2-(4-imidazoyl) cyclopropyl derivatives
|
|
US6008240A
(en)
*
|
1997-12-15 |
1999-12-28 |
Gliatech, Inc. |
2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
|
|
WO2000042023A1
(en)
|
1999-01-18 |
2000-07-20 |
Novo Nordisk A/S |
Substituted imidazoles, their preparation and use
|
|
US7265115B2
(en)
|
1999-01-29 |
2007-09-04 |
Abbott Laboratories |
Diazabicyclic CNS active agents
|
|
US6908926B1
(en)
|
1999-04-16 |
2005-06-21 |
Novo Nordisk A/S |
Substituted imidazoles, their preparation and use
|
|
US6114350A
(en)
*
|
1999-04-19 |
2000-09-05 |
Nen Life Science Products, Inc. |
Cyanine dyes and synthesis methods thereof
|
|
US6437147B1
(en)
|
2000-03-17 |
2002-08-20 |
Novo Nordisk |
Imidazole compounds
|
|
US6610721B2
(en)
|
2000-03-17 |
2003-08-26 |
Novo Nordisk A/S |
Imidazo heterocyclic compounds
|
|
WO2002013821A1
(en)
|
2000-08-17 |
2002-02-21 |
Gliatech, Inc. |
Novel alicyclic imidazoles as h3 agents
|
|
US20040006120A1
(en)
*
|
2000-08-21 |
2004-01-08 |
Yates Stephen L |
Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
|
|
AU2002256967A1
(en)
*
|
2000-10-30 |
2002-09-12 |
Schering Corporation |
Treating or reducing the risk of cardiovascular disease
|
|
BR0308118A
(pt)
*
|
2002-03-01 |
2005-01-11 |
Warner Lambert Co |
Método para o tratamento de osteoartrite
|
|
EP1720847A1
(en)
*
|
2004-02-02 |
2006-11-15 |
Pfizer Products Incorporated |
Histamine-3 receptor modulators
|
|
EP1720861A2
(en)
|
2004-02-25 |
2006-11-15 |
Eli Lilly And Company |
Histamine h3 receptor antagonists, preparation and therapeutic uses
|
|
BRPI0509298A
(pt)
|
2004-04-01 |
2007-09-18 |
Lilly Co Eli |
composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
|
|
EP1756051B1
(en)
*
|
2004-06-02 |
2012-09-12 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
CN101006082B
(zh)
|
2004-08-23 |
2010-09-29 |
伊莱利利公司 |
组胺h3受体药剂、制备方法和治疗用途
|
|
JP5057982B2
(ja)
|
2004-10-18 |
2012-10-24 |
イーライ リリー アンド カンパニー |
ヒスタミンｈ３受容体阻害剤、製造及び治療的使用
|
|
BRPI0608523A2
(pt)
*
|
2005-03-17 |
2010-11-16 |
Lilly Co Eli |
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir receptor de histamina h3 em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, para tratar ou prevenir obesidade e para tratar ou prevenir um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
|
|
AU2006232871B9
(en)
|
2005-04-01 |
2011-11-24 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
EP1707203A1
(en)
|
2005-04-01 |
2006-10-04 |
Bioprojet |
Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
|
|
EP1717235A3
(en)
|
2005-04-29 |
2007-02-28 |
Bioprojet |
Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
|
|
EP1717233A1
(en)
*
|
2005-04-29 |
2006-11-02 |
Bioprojet |
Histamine H3-receptor ligands and their therapeutic application
|
|
EP1938838A4
(en)
*
|
2005-09-15 |
2009-09-23 |
Banyu Pharma Co Ltd |
HISTAMINE H3 AGONIST FOR USE AS A THERAPEUTIC AGENT AGAINST LIPID / GLUCOSE METABOLISM
|
|
EP1942104A1
(en)
|
2006-12-20 |
2008-07-09 |
sanofi-aventis |
Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
|
|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
US8859555B2
(en)
|
2009-09-25 |
2014-10-14 |
Oryzon Genomics S.A. |
Lysine Specific Demethylase-1 inhibitors and their use
|
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
WO2011106106A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
CA2796726C
(en)
|
2010-04-19 |
2021-02-16 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
BR112013002164B1
(pt)
|
2010-07-29 |
2021-11-09 |
Oryzon Genomics S.A. |
Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
EP2768805B1
(en)
|
2011-10-20 |
2020-03-25 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
JP6046154B2
(ja)
|
2011-10-20 |
2016-12-14 |
オリソン ヘノミクス エセ． アー． |
Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
|
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|